About
Jake is a senior associate in the Life Sciences Transactions team of our New York office. Prior to joining Freshfields, Jake worked at a global law firm where his practice focused on complex litigation with an emphasis on intellectual property matters in the fields of pharmaceuticals and biotechnology.
Jake received his J.D., magna cum laude, from Penn Law where he studied Intellectual Property Law. He also earned his Bachelor of Arts degree in Chemistry, magna cum laude from the University of Pennsylvania.
Additional Information
- AbbVie in its exclusive licensing arrangement with RemeGen for RC148, a novel investigational PD-1/VEGF-targeted bispecific antibody, and on its strategic option-to-license agreement with Simcere Zaiming to develop a novel trispecific antibody candidate in multiple myeloma.
- Cartography Biosciences on its collaboration and license agreement with Pfizer for the discovery of tumor selective antigens.
- Insmed in the acquisition of an antibody program.
- Cullinan Therapeutics on its license agreement with Genrix Bio for ex-China rights to velinotamig, a clinical-stage bispecific T cell engager.
- Grünenthal on its acquisition of Valinor Pharma and its product Movantik® (naloxegol).
- SERB Pharmaceuticals on its acquisition of RSDL® (Reactive Skin Decontamination Lotion) kit from Emergent BioSolutions Inc., and on its license from SFJ Pharmaceuticals to obtain exclusive U.S. rights to bentracimab, a ticagrelor reversal agent.
- AstraZeneca in its $2.4 billion acquisition of Fusion Pharmaceuticals Inc., and its $1 billion acquisition of Amolyt Pharma.
- Novartis on its €2.7 billion acquisition of MorphoSys AG, and on its collaboration and license agreement with Ionis Pharmaceuticals for the discovery, development and commercialization of a novel medicine for patients with certain cardiovascular diseases.
- Basilea Pharmaceutica on its acquisition from Pfizer of Fosmanogepix, a clinical-stage antifungal candidate with a novel mechanism of action to treat invasive mold infections.
- BioCryst in its license agreement with Clearside Biomedical, Inc. to to develop and commercialize BioCryst’s proprietary compound, BCX-4161 or avoralstat, in combination with Clearside’s proprietary drug delivery device, for the treatment and prevention of certain eye diseases.
- Moderna on its collaboration with CARsgen Therapeutics for the development of a combination therapy consisting of an mRNA-based cancer vaccine and an autologous CAR-T therapy.
- PhenomeX in its agreement to sell to Bruker Corporation.
Jake A. Silvers
Senior Associate
New York Office
3 World Trade Center
175 Greenwich Street, 51st Floor
New York, NY 10007